Patents by Inventor Kieran Geoghegan

Kieran Geoghegan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prolonged delivery of peptides
    Publication number: 20060003918
    Abstract: There are disclosed methods for the treatment of non-insulin dependent diabetes mellitus in a mammal comprising the prolonged administration of GLP-1 (7-37), and related peptides. Also disclosed are compositions to prolong the administration of the peptides.
    Type: Application
    Filed: December 7, 2004
    Publication date: January 5, 2006
    Inventors: Yesook Kim, William Lambert, Hong Qi, Robert Gelfand, Kieran Geoghegan, Dennis Danley
  • Methods of using GST-Omega-2
    Publication number: 20050064519
    Abstract: The present invention relates to GST-Omega-2 and methods of using this diarylsulfonylurea binding protein (DBP) as a therapeutic target for the identification of agents that suppress the release of inflammatory mediators such as interleukin IL-1 and IL-18.
    Type: Application
    Filed: April 5, 2004
    Publication date: March 24, 2005
    Inventors: Christopher Gabel, Kieran Geoghegan, Jose Perez
  • Diarylsulfonylurea binding proteins
    Publication number: 20030027217
    Abstract: The present invention relates to the identification of diarylsulfonylurea binding proteins (DBPs) as therapeutic targets for agents that suppress the release of inflammatory mediators such as interleukin IL-1 and IL-1&bgr;.
    Type: Application
    Filed: August 21, 2002
    Publication date: February 6, 2003
    Applicant: Pfizer Inc.
    Inventors: Christopher A. Gabel, Richard J. Griffiths, James F. Eggler, Mark A. Dombroski, Kieran Geoghegan
  • Methods of screening compounds for their ability to inhibit the production of inflammatory cytokines
    Patent number: 6461822
    Abstract: The present invention relates to the identification of diarylsulfonylurea binding proteins (DBPs) as therapeutic targets for agents that suppress the release of inflammatory mediators such as interleukin IL-1 and IL-1&bgr;.
    Type: Grant
    Filed: August 31, 1999
    Date of Patent: October 8, 2002
    Assignee: Pfizer Inc.
    Inventors: Christopher A. Gabel, Richard J. Griffiths, James F. Eggler, Mark A. Dombroski, Kieran Geoghegan